|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||38.71 - 38.98|
|52 Week Range||37.20 - 44.54|
|PE Ratio (TTM)||43.64|
|Dividend & Yield||1.99 (5.12%)|
|1y Target Est||N/A|
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
Sir, Joining in the discussion about GlaxoSmithKline's new plans, I find chief executive Emma Walmsley's strategic thinking on research and development questionable. I suggest it shows the terrible consequences ...
The drug would be the first such treatment in Europe.